Anti-malarials
Fake anti malarials: start with the facts
9
Donor support for quality assurance and pharmacovigilance of anti malarials in malaria endemic countries
10
Private sector drug shops frequently dispense parenteral anti malarials in a rural region of Western Uganda
9
Susceptibility of human Plasmodium knowlesi infections to anti malarials
7
Quality of anti malarials collected in the private and informal sectors in Guyana and Suriname
8
A framework for assessing the risk of resistance for anti malarials in development
11
Saleability of anti malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)
8
Access to artesunate amodiaquine, quinine and other anti malarials: policy and markets in Burundi
9
Biological evaluation of hydroxynaphthoquinones as anti malarials
6
Natural anti–malarials: A bright hope
7
Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti malarials
9
Two successful decades of Swiss collaborations to develop new anti malarials
7
Atovaquone and quinine anti malarials inhibit ATP binding cassette transporter activity
8
Were medicine quality and pharmaceutical management contributing factors in diminishing artemisinin efficacy in Guyana and Suriname?
5
Re imagining adherence to treatment from the “other side”: local interpretations of adverse anti malarial drug reactions in the Peruvian Amazon
7
Frequency and correlates of malaria over treatment in areas of differing malaria transmission: a cross sectional study in rural Western Kenya
9
Predictors of hyperlactataemia among children presenting with malaria in a low transmission area in The Gambia
11
Application of loop analysis for evaluation of malaria control interventions
15
Patterns of anti malarial drug treatment among pregnant women in Uganda
8
Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets a provider perspective
15